NTV Asset Management LLC Sells 77 Shares of Amgen Inc. (NASDAQ:AMGN)

NTV Asset Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,927 shares of the medical research company’s stock after selling 77 shares during the period. NTV Asset Management LLC’s holdings in Amgen were worth $3,147,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of AMGN. Connecticut Wealth Management LLC boosted its position in Amgen by 17.1% during the fourth quarter. Connecticut Wealth Management LLC now owns 2,064 shares of the medical research company’s stock valued at $594,000 after acquiring an additional 301 shares during the last quarter. Ellerson Group Inc. ADV lifted its stake in shares of Amgen by 0.7% in the 4th quarter. Ellerson Group Inc. ADV now owns 11,275 shares of the medical research company’s stock valued at $3,247,000 after purchasing an additional 80 shares during the period. TCG Advisory Services LLC acquired a new position in shares of Amgen in the 4th quarter valued at about $562,000. Forte Capital LLC ADV boosted its position in shares of Amgen by 2.7% during the 4th quarter. Forte Capital LLC ADV now owns 4,134 shares of the medical research company’s stock valued at $1,191,000 after purchasing an additional 108 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in Amgen during the fourth quarter worth approximately $542,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of several research analyst reports. BMO Capital Markets lifted their price target on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research note on Friday. TD Cowen dropped their price target on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a report on Friday. UBS Group boosted their price objective on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a report on Friday. Finally, Truist Financial reiterated a “buy” rating and issued a $320.00 target price on shares of Amgen in a report on Friday, April 12th. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $305.05.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by insiders.

Amgen Stock Performance

AMGN traded up $32.90 during midday trading on Friday, reaching $311.29. The company had a trading volume of 9,644,682 shares, compared to its average volume of 2,279,398. The business has a 50-day moving average price of $274.95 and a two-hundred day moving average price of $281.50. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The stock has a market cap of $166.97 billion, a PE ratio of 44.47, a P/E/G ratio of 2.69 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 145.62% and a net margin of 12.74%. The business had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. During the same quarter in the prior year, the business earned $3.98 earnings per share. Amgen’s revenue for the quarter was up 22.0% on a year-over-year basis. On average, sell-side analysts expect that Amgen Inc. will post 19.43 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 2.89%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.